ProfileGDS5678 / 1432130_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 66% 69% 68% 67% 70% 70% 69% 69% 68% 71% 69% 67% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3149270
GSM967853U87-EV human glioblastoma xenograft - Control 23.9461266
GSM967854U87-EV human glioblastoma xenograft - Control 34.2824269
GSM967855U87-EV human glioblastoma xenograft - Control 44.2185268
GSM967856U87-EV human glioblastoma xenograft - Control 54.0481367
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3805370
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3424270
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2303369
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2265269
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.188668
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4088871
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2301869
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0453167
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2326769